With a little bit of help from its friends

Creativity rules in today's low-financing biotech world. One of a growing list of companies that have found novel funding sources is Seragen Inc., which just completed a $23.8 million bank financing.

Bank loans are not exactly everyday occurrences in biotech, and to top it off SRGN obtained terms similar to what a AAA-rated company would pay: a small markup over the London Interbank Offer Rate (LIBOR)...